GO TO CMA Home
GO TO Inside CMA
GO TO Advocacy and Communications
GO TO Member Services
GO TO Publications
GO TO Professional Development
GO TO Clinical Resources

GO TO What's New
GO TO Contact CMA
GO TO Web Site Search
GO TO Web Site Map


CMAJ
CMAJ - January 26, 1999JAMC - le 26 janvier 1999

Prostate cancer: 9. Treatment of advanced disease

Table 2: Indications for use of anti-androgens
To prevent the flare phenomenon during the first month of LH-RH agonist treatment:
  cyproterone acetate (50 mg twice daily) plus DES (0.1 mg daily)
  or cyproterone acetate (150 mg orally, twice daily)
  or cyproterone acetate (150 mg orally, twice daily)
  or a nonsteroidal anti-androgen

To treat hot flushes after medical or surgical castration:
  cyproterone acetate (50 mg once daily)

To treat biochemical (indicated by rising PSA level) or clinical progression of disease in patients treated with LH-RH agonists, orchiectomy or low-dose cyproterone and mini-dose DES:
  3-month trial with a nonsteroidal anti-androgen (bicalutamide, flutamide
  or nilutamide),to be continued only if there is a decrease in serum
  PSA level

Note: PSA = prostate-specific antigen.

[Return to text]